Clinical trials
beta-Thalassemia trials in Greece
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 6 |
| Novartis Pharmaceuticals | 2 |
| University of Washington | 2 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 1 |
| ApoPharma | 1 |
| Consorzio per Valutazioni Biologiche e Farmacologiche | 1 |
| Cyprus Institute of Neurology and Genetics | 1 |
| Ersi Voskaridou | 1 |
| Genetix Biotherapeutics Inc. | 1 |
| Ionis Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| beta-Thalassemia | 22 |
| Thalassemia | 6 |
| Iron Overload | 2 |
| alpha-Thalassemia | 2 |
| Anemia, Sickle Cell | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Hemochromatosis | 1 |
| Hemoglobinopathies | 1 |
| Hemosiderosis | 1 |
| Insulin Resistance | 1 |
Trials
Showing 51 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.